- DKK36.31bn
- DKK45.28bn
- DKK24.63bn
Brief: Lundbeck Raises Financial Guidance For 2024
Brief: Lundbeck Q2 Revenue DKK 5,453 Million
Brief: Lundbeck, Takeda Modify Collaboration Agreement For Trintellix In U.S.
Brief: Lundbeck And Otsuka Announce FDA Acceptance Of SNDA Filing For Brexpiprazole
Brief: H Lundbeck Explores New Area In Neurohormonal Dysfunctions
Europe Research Roundup: Britvic, Energean, Pandora
Brief: H Lundbeck Maintains 2024 Financial Guidance
Brief: Lundbeck Q1 Revenue DKK 5,288 Million
Brief: Lundbeck, Otsuka Submit sNDA For FDA Review Of Brexpiprazole And Sertraline Combination
Otsuka And Lundbeck Submit SNDA For FDA Review Of Brexpiprazole And Sertraline Combination As Potential Treatment For Ptsd
Brief: Lundbeck Announces Advancement Of Lu AG09222 Clinical Development
Brief: H Lundbeck Says Data Suggests MAB Potential Slowing Clinical Progression
Live Markets: The mighty dollar's comeback
Live Markets: Searching for hidden gems? Stop here
DB upgrades Lundbeck to 'buy' on promising drug prospects in 2024
Brief: Lundbeck Q4 Revenue DKK 4,978 Million
Brief: H Lundbeck: Supportive Phase Ii Results With LU AF82422 In Treatment Of Multiple System Atrophy
'A tougher narrative into 2024' - MS starts Lundbeck with 'underweight'
Europe Research Roundup: BAE Systems, Entain, L'Oreal